Bioversys AG Asset Resilience Ratio

Latest as of December 2024: 17.16%

Bioversys AG asset resilience ratio. Bioversys AG (BIOV) has an Asset Resilience Ratio of 17.16% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Bioversys AG fund operations to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CHF6.00 Million

≈ $7.59 Million USD Cash + Short-term Investments

Total Assets

CHF34.96 Million

≈ $44.19 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio of Bioversys AG (2024–2024)

Asset resilience ratio of Bioversys AG from 2024 to 2024. This chart shows how Bioversys AG's Asset Resilience Ratio has changed over time. Read how much debt does Bioversys AG carry for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Bioversys AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Bioversys AG.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF0.00	0%
Short-term Investments	CHF6.00 Million	17.16%
Total Liquid Assets	CHF6.00 Million	17.16%

Asset Resilience Insights

Good Liquidity Position: Bioversys AG maintains a healthy 17.16% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Bioversys AG Industry Peers by Asset Resilience Ratio

Compare Bioversys AG's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Hyloris Developmentsen Sa BR:HYL	Biotechnology	1.36%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Oruka Therapeutics, Inc. NASDAQ:ORKA	Biotechnology	53.11%
Gempharmatech Co. Ltd. A SHG:688046	Biotechnology	23.95%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	74.48%
Inventiva S.A PA:IVA	Biotechnology	52.73%
Sunmax Biotechnology Co Ltd TWO:4728	Biotechnology	10.53%
Guangdong VTR Bio-Tech Co Ltd SHE:300381	Biotechnology	4.98%

Bioversys AG Asset Resilience Ratio by Year (2024–2024)

Bioversys AG asset resilience ratio by year from 2024 to 2024. The table below shows the annual Asset Resilience Ratio data for Bioversys AG.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	17.16%	CHF6.00 Million ≈ $7.59 Million	CHF34.96 Million ≈ $44.19 Million	--

pp = percentage points

About Bioversys AG

SW:BIOV Switzerland Biotechnology

Market Cap

$168.76 Million

CHF133.48 Million CHF

Market Cap Rank

#17228 Global

#177 in Switzerland

Share Price

CHF22.80

Change (1 day)

+1.33%

52-Week Range

CHF21.50 - CHF30.00

All Time High

CHF36.30